欢迎来到天天文库
浏览记录
ID:21795802
大小:386.00 KB
页数:73页
时间:2018-10-24
《ichm7(step4)基因毒性杂质评估和控制◆中英》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、ASSESSMENTAND CONTROLOF DNAREACTIVE(MUTAGENIC)IMPURITIESIN PHARMACEUTICALSTOLIMIT POTENTIAL CARCINOGENIC RISK为限制潜在致癌风险而对药物中DNA活性(诱变性)杂质进行的评估和控制M7Current Step4 versiondated23June2014ThisGuidelinehasbeendevelopedbytheappropriateICHExpertWorkingGroupandhasbeensubjecttoconsultati
2、onbytheregulatoryparties,inaccordancewiththeICHProcess.AtStep4oftheProcessthefinaldraftisrecommendedforadoptiontotheregulatorybodiesoftheEuropeanUnion,JapanandUSA. M7DocumentHistory 文件历史Code 文件代码History 历史Date 日期M7ApprovalbytheSteeringCommitteeunderStep2andreleaseforpubliccon
3、sultation.第2阶段由筹委会批准,公开征求意见6February2013M7ApprovalbytheSteeringCommitteeunderStep4andrecommendationforadoptiontothethreeICHregulatorybodies.第4阶段由筹委会批准,推荐ICH三方药监局采用5June2014CurrentStep4version 现行版本第4阶段M7Corrigendumtofixtypographicalerrorsandreplaceword“degradants”with“degradat
4、ionproducts”throughoutthedocument.修正输入错误,将全文中“degradants”替换成“degradationproducts”.23June2014 LegalNotice: Thisdocumentisprotectedbycopyrightandmaybeused,reproduced,incorporatedintootherworks,adapted,modified,translatedordistributedunderapubliclicenseprovidedthatICH'scopyright
5、inthedocumentisacknowledgedatalltimes.Incaseofanyadaption,modificationortranslationofthedocument,reasonablestepsmustbetakentoclearlylabel,demarcateorotherwiseidentifythatchangesweremadetoorbasedontheoriginaldocument.Anyimpressionthattheadaption,modificationortranslationoftheo
6、riginaldocumentisendorsedorsponsoredbytheICHmustbeavoided.Thedocumentisprovided"asis"withoutwarrantyofanykind.InnoeventshalltheICHortheauthorsoftheoriginaldocumentbeliableforanyclaim,damagesorotherliabilityarisingfromtheuseofthedocument.Theabove-mentionedpermissionsdonotapply
7、tocontentsuppliedbythirdparties.Therefore,fordocumentswherethecopyrightvestsinathirdparty,permissionforreproductionmustbeobtainedfromthiscopyrightholder.ASSESSMENTAND CONTROLOF DNAREACTIVE (MUTAGENIC)IMPURITIESIN PHARMACEUTICALSTO LIMIT POTENTIALCARCINOGENIC RISK为限制潜在致癌风险而对药物
8、中DNA活性(诱变性)杂质进行的评估和控制ICHHarmonisedTripartiteGuidelineICH三方协调指南Having
此文档下载收益归作者所有